Acturadar.comFrance in real time

Story no.231OngoingHealthNotableCôte-d'Or +228 Oct → 14 Nov22 facts · 80 art.

Anti-obesity drugs in France: controls, reimbursement and off-label uses

In early November 2026, customs authorities step up parcel checks to curb trafficking of appetite suppressants such as Wegovy, while the arrival of oral anti-obesity treatments prompts economic analyses and a study on reduced consumption of sugary products among treated patients. The health risks of Ozempic and Wegovy, particularly in cases of off-label use, are highlighted, and the 100-million-euro allocation for obesity reimbursement is deemed insufficient. Influencers are then singled out for promoting these drugs to boast about their slimness, patients turn to parallel markets, and health professionals warn about weight-loss injections. In mid-November, a Lilly France campaign is suspected of covert advertising for Mounjaro, specialized obesity centers are saturated since the reimbursement of Wegovy and Mounjaro in June, and research explores new therapeutic uses while Wegovy costs more than 2,300 euros per year outside eligibility criteria.

In brief

Ongoing story bringing together 22 events nationwide, followed from 28 October 2026 to 14 November 2026. 80 articles from 23 sources (health); last updated on 14 November 2026 at 15:40.

·
01

Who is covering it, and from what angle

Method
15Left23 %
47Centre71 %
4Right6 %

66 articles of rated outlets · 14 unrated outside the bar · 23 sources (80 art.) · the three sides talk about it · outlets: left 5, centre 15, right 2

Angle comparison for the whole story

The three sides cover the same issue (the arrival of oral Wegovy, French enthusiasm, risks and trafficking), but differ in angle: the left prioritizes testimonies and individual health risks, the center extensively covers the Ifop poll and practical alerts, the right highlights the market explosion, side effects and economic and regulatory aspects.

Left

Highlights personal testimonies (a patient who lost weight without medication, a formerly obese person warning about Wegovy), health risks linked to off-label use and recourse to parallel markets, as well as changes in eating habits.

Centre

Extensively covers the Ifop poll (one in five French people tempted, even without being obese), health professionals' alerts on injections and harmful substances, influencers diverting medications, and customs controls against trafficking.

Right

Highlights the explosion of the appetite suppressant market and the multiplication of side effects, the non-reimbursable nature of oral Wegovy, consultation waiting times and the economic aspects of treatment.

Written by an AI from headlines and extracts only of all events in the story · 14 Nov, 15h44

02

What is established

Method

Confirmed by several sources(5)

Single source so far(5)

AI cross-check of the headlines and extracts of 28 articles (18 outlets) · “confirmed” = reported by at least two independent outlets · 1 Nov, 22h41

Checked on the web(3)

Automatic web search, official sources first · “contradicted” only when an official source is cited

03

Timeline

newest first

Outlets:LeftCentreRightUncategorised· badge = severity

04

In figures

The activity

22 faits

Latest activity 3 days ago

28 Oct14 Nov

Affected departments

Reported toll

Amounts cited169 euros · 235 euros · 100 millions · 2 300 €

Highest number recorded in 8 article(s), automatically extracted: please check sources.

05

Further reading